Mayo Clinic Reports Possible New Therapy for Patients with Platinum-Resistant Ovarian Cancer
SAN FRANCISCO — Mayo Clinic today reported promising interim results from a Phase II trial of a new combination therapy for patients with recurrent ovarian cancer that is resistant to platinum therapy. Thirty-three percent of study participants achieved either complete or partial tumor regression from the therapy, which combines flavopiridol and cisplatin.